Biotest AG: Forecast for turnover and profit raised
Biotest AG / Forecast
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest: Forecast for turnover and profit raised
Dreieich, 27 May 2008. The Managing Board of Biotest AG raised the
company's forecast for turnover and profit in the current year. The
Management now expects sales of EUR 420 million in 2008, following EUR
326.4 million in the previous year. Until now the target had been EUR 400
million. Earnings before interest and tax (EBIT) are expected to be by 20%
higher than in the previous year. The earlier forecast was a raise by 10%.
Disclaimer
This document contains future-oriented statements regarding macroeconomic
development as well as the business outlook, profitability, financial
position and asset situation of Biotest AG and its subsidiaries. These
statements are based on the current plans, estimates, forecasts and
expectations of the company and therefore are subject to risks and elements
of uncertainty, which could lead to significant deviation from the expected
development in the actual results. The future-oriented statements are only
valid at the time of publication. Biotest does not intend to update the
future-oriented statements and does not assume any responsibility for doing
this.
About Biotest
Biotest is a pharmaceutical, biotherapeutic and diagnostics company
involved in research and production, specialising in the areas of
application of immunology and hematology. In the Pharmaceutical segment
Biotest develops and markets immunoglobulin, coagulation factors and
albumins that are produced from human blood plasma and can be used to treat
diseases of the immune system and the hematopoietic system. In the
Biotherapeutic segment Biotest promotes the clinical development of
monoclonal antibodies, including those used to treat rheumatism and
leukaemia. The Diagnostics segment includes reagents and systems for
microbiology that are primarily used for hygiene monitoring, as well as for
immunologic diagnostics that, for example, can be applied in blood
transfusions and transplants. Biotest employees approximately 1800 people
worldwide. Shares of Biotest AG are listed on the SDAX of the Deutsche
Börse.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, Germany, www.biotest.de
Dr. Michael Ramroth
Tel.: +49 (0) 6103 801-338
Fax: +49 (0) 6103 801-347
E-mail: michael_ramroth@biotest.de
WKN, ISIN Common shares: 522720, DE0005227201
WKN, ISIN Preferred shares: 522723, DE0005227235
Quoted: Prime Standard/Amtlicher Handel (official trading)
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
27.05.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-8 80
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
